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Cisplatin.mduced alterations in renal structure, ammoniagenesis, and
gluconeogenesis of rats. Cisplatin [cis-diamminedichloroplatinum (II):
CDDP] is a widely used cancer chemotherapeutic agent which has been
shown to cause dose-related acute renal failure. The kidney damage is
histologically characterized by widespread tubular necrosis, predomi-
nantly found in the third segments (S3) of the proximal tubules. To
identify the intranephron targets of CDDP more precisely, we examined
alterations in ammoniagenesis (AMG) and gluconeogenesis (GLG)
using rat kidney slices (for AMG and GLG), tubule suspensions (for
GLG), and microdissected nephron segments (for AMG). Litramicro-
assay of AMG was carried out using the enzymatic cycling method, and
GLG was measured by the HK/G6PHD method. GLG obtained from
kidney slices and tubule suspensions on day 3 and day 7 following
CDDP treatment did not change significantly from levels in control rats.
In contrast, AMG increased on day 3 in the first and third kidney slices
cut from the surface inward and decreased significantly on day 7 in the
third and fourth slices. Microdissected nephron segments examined on
day 7 showed decreased AMG in the second segments (S2; 20.3 7.7
pmol/mm/l5 mm vs. 78.7 9.7 for control, P < 0.005) and the third
segments (S3; 26.3 14.4 pmol/mm/l5 mm vs. 79.2 7.8 for control,
P < 0.005) of the proximal tubules. Additionally, we observed morpho-
logical changes under light microscopy to examine the relationship
between metabolism and morphology. On day 3 following the CDDP
treatment, typical acute tubular necrosis was seen primarily localized in
the outer stripe of the outer medulla, while on day 7 the lesion appeared
to be recovering. Our data imply a prominent dissociation between
renal metabolic and morphologic changes induced by CDDP. First,
AMG in a distinct part of the kidney was enhanced on day 3, suggesting
a compensatory hyperfunction of AMG in the early proximal tubule
(SI) or thick ascending limb of Henle (TAL), at a time when morpho-
logical damage was approaching maximum. Second, AMG in both S2
and S3 was significantly reduced on day 7 possibly because of a high
demand for amino acids for protein synthesis during tubular epithelial
regeneration.
Cisplatin [cis-diamminedichloroplatinum (II): CDDP], a
widely used chemotherapeutic agent, has been shown to cause
dose-related acute renal failure (ARF) both in human clinical
use [1—5] and in animal studies. In rats, a number of morpho-
logic studies have been reported that emphasize CDDP-induced
ARF involving selective damage to S3 of the proximal tubule
located in the outer stripe of the outer medulla [6—9]. In
addition, the clinical course of CDDP-induced ARF revealed
increased levels of serum creatinine, blood urea nitrogen, and
uric acid. This ARF was accompanied by enzymuria involving
N-acetyl-j3-D-glucosaminidase [4, 10] and y-glutamyl transpep-
tidase [11], urinary loss of a small molecular protein, /32-
microglobulin [4], and amino aciduria which indicated wide-
spread proximal tubular dysfunction. However, there has been
little documentation of investigations into the metabolic
changes in renal tubular function, which are indispensable for
supporting these reported morphologic and clinical manifesta-
tions following CDDP treatment.
In previous studies, we demonstrated the functional hetero-
geneity of normal rat nephron segments by directly measuring
glucose and ammonia production with ultramicro-assays [12,
13]. Those results showed that Si plays the major role in
gluconeogenesis (GLG), with S2 and S3 participating to a lesser
extent. Ammoniagenesis (AMG), however, is more widely
distributed in the nephron with not only S 1 and S2 but also S3
segments.
In the present study, we exunined the changes in GLG and
AMG after CDDP administration using rat kidney slices, tubule
suspensions, and microdissected nephron segments to confirm
the target sites of CDDP. These results were compared with
morphologic changes. The preliminary results of this work have
already been reported [14].
Methods
Animals
Male Sprague-Dawley rats (Saitama Experimental Laborato-
ries, Saitama, Japan) weighing 160 to 220 g were used in this
study. All rats were fed a diet of standard rat chow (Oriental
Yeast, Osaka, Japan) and were allowed water ad libitum. The
rats were given a single intraperitoneal injection of CDDP
(Sigma Chemical, St. Louis, Missouri, USA) in a dose of 5
mg/kg body wt. Control rats were injected with saline. Rats
were weighed prior to (day 0) and after CDDP treatment (day 3,
day 4, and day 7). The metabolic studies for GLG and/or AMG
were performed on days 1, 2, 3, 4, and 7. Additionally, at the
time of sacrifice, on day 3 and day 7, blood and the prior 24
hours' urine were collected for the determination of serum
creatinine and creatinine clearance.
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CDDP, coliagenase (type 1), bovine serum albumin (BSA)
and a-ketoglutarate were obtained from Sigma Chemical Co.
Nicotinamide adenine dinucleotide phosphate (NADP), adeno-
sine triphosphate (ATP), glucose-6-phosphate dehydrogenase
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(G6PDH), hexokinase (HK), glutamate dehydrogenase
(GLDH), alcohol dehydrogenase, malate dehydrogenase, and
pyruvate were purchased from Boehringer (Mannheim, Germa-
ny). Nicotinamide adenine dinucleotide (NAD) and its reduced
form (NADH) were from Oriental Yeast, and L-glutamine was
from the Protein Research Foundation (Osaka, Japan). All
other chemicals were of the analytical grade from commercial
sources.
Preparations for morphological studies
The kidneys were fixed by the intravascular perfusion of 2%
paraformaldehyde and 1% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.4 [15]. The excised kidneys were transected and
placed in the same fixative. Cross sections were paraffin-
embedded, cut at 3 jim, and stained with hematoxylin and eosin
or by the periodic acid-Schiff technique, and examined by
routine light microscopy.
Preparation of kidney slices
After the rats were decapitated, their kidneys were perfused
with ice-cold Hanks solution and removed. A rectangular block
was cut out along the corticomedullary axis, and four 1 mm
slices were cut from the surfaces inward. Each slice was
incubated aerobically (95% 02/5% C02) for 30 minutes (for
gluconeogenesis, GLG) or 15 minutes (for ammoniagenesis,
AMG).
Preparation of kidney cortical tubule suspensions and
nephron segments
The methods for preparing the tubule suspensions and neph-
ron segments were the same as previously described [16, 17]. In
brief, after the left kidney was perfused with modified Hanks
solution (1 m CaC12) containing 0.075% collagenase and 0.1%
BSA and excised, the cortex was cut off, cut into 0.5 mm slices,
and incubated aerobically at 37°C for 30 minutes in collagenase
solution. Then, the following tubule suspensions or nephron
segments were prepared from these slices.
For tubule suspensions, slices were washed with ice-cold
modified Hanks solution (0.25 mivi CaCI2) and rigorously dis-
persed by a voltex mixer. Then, the upper turbid medium was
transferred to a 50 ml siliconized Erlenmeyer flask and placed
on ice for three minutes. The upper fraction containing almost
all cells was sieved through a set of nylon meshes graded from
1 mm to 40 pm in diameter, and the residue was centrifuged for
10 minutes at 300 x g. The precipitate was resuspended and
washed three or four times with Krebs-Henseleit buffer (KH),
and the resultant precipitate was used as a tubule suspension.
To prepare nephron segments, slices were placed in cold
Hanks solution, and the following segments were microdis-
sected under stereomicroscope using silicon-coated stainless
steel needles. Sl of the proximal tubule was dissected within 1
mm from the glomerulus, and S2 of the proximal tubule, the
upper part of the straight portion, was obtained from the
superficial part of the cortex. S3 was dissected within 1 mm of
the terminal portion of the proximal tubule connected to the
beginning of the thin descending limb of Henle's loop. The
cortical thick ascending limb of Henle's loop (TAL), the distal
convoluted tubule together with the connecting tubule (DT),
and the cortical collecting tubule (CCT) were microdissected
from the cortex.
Measurements of gluconeogenic activity from kidney slices or
tubule suspensions
Glucose synthesized by kidney slices or tubule suspensions
was measured by the HK/G6PDH method [18]. The practical
procedure is described in detail elsewhere [161. In brief, kidney
slices or tubule suspensions in 0.5 ml KH were incubated
aerobically at 37°C for 30 minutes with 0.5 ml KH alone
(control) or containing one of the following substrates (4 mrs):
pyruvate, malate, and glutamine. After incubation, the contents
were transferred to other tubes, boiled for one minute, and
centrifuged at 800 x g for 15 minutes. Each 50 p1 of the
supernatant was added to 50 p1 of an incubation mixture
containing 17 mrs ATP, 1.4 mrvi NADP, 5 U/mi G6PDH, and 2
U/mI HK in 0.2 M triethanolamine/HC1, pH 7.5. The amount of
NADPH which was equimolar to the amount of glucose pro-
duced, converted from NADP, was measured with a spectro-
photometer.
Gluconeogenic activities were estimated as nmol of newly
produced glucose per mg tissue dry-weight of kidney slices and
as nmol of glucose per mg tissue protein of tubule suspensions,
which are designations generally used in the literature [16, 20].
Measurements of ammonia genic activity from kidney slices
and nephron segments
Ammonia produced from kidney slices was measured using
samples obtained as described in the previous protocol for
GLG. Samples were incubated for 15 minutes in 0.5 ml KH with
or without 2 mrvi glutamine (final concentration). Each 20 p1
supernatant was added to 10 p1 of 0.05 N HC1, and the total 30
p1 sample containing NH4 was added to 30 p1 reagent contain-
ing 20 mts a-ketoglutarate, 0.48 m NADH and 24 U/ml GLDH
in 200 mri Tris/HC1, pH 8.0. The amount of NAD converted
from NADH, which was equimolar to the produced NH4, was
measured with a spectrophotometer [21].
Microdissected individual nephron segments obtained as
described previously for GLG were incubated with or without 2
mM glutamine [12]. The minute amounts of ammonia synthe-
sized by the isolated nephron segments were measured using
the enzymatic cycling method of NAD [22]. The malate pro-
duced was measured fluorometrically by an Aminco fluorom-
eter (American Instrument Co., Silver Spring, Maryland,
USA).
Ammoniagenic activity was estimated from the difference in
amount of ammonia produced with and without glutamine and
calculated as nmol of ammonia per mg tissue dry-weight of
kidney slices and as pmol ammonia per mm tubule length of the
individual nephron segments.
Measurements of tissue dry-weight, protein content, and
creatinine concentration
Tissue dry-weights of the kidney slices were determined after
the blotted samples were heated at 110°C for 60 minutes. The
protein content in each tubule suspension sample was measured
by the method of Lowry et al [23]. Creatinine concentrations in
serum and 24-hour urine samples were determined by the
standard method.
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Table 1. Changes in body weights following C
i.p.) in male rats DDP injection (5 mg/kg
Day
Control CDDP
g
0
3
4
7
171±5(N=37)
202±ll(N=6)
197 14 (N = 8)
2l1±5(N=24)
184±6(N=39)
179±3(N=8)a
157 10 (N =
189±9(N=28)a
a P < 0.05 vs. respective control
b P < 0.05 vs. day 0 of CDDP
Analysis of the results
All data were expressed as means SE. The differences were
evaluated statistically by the paired or unpaired Student's
t-test, as appropriate. Data on glucose production from three
different substrates by control tubule suspensions were com-
pared using variance analysis. The differences with a P value of
<0.05 were considered significant.
Results
Changes in body weight and renal function following CDDP
injection
Following a single injection of CDDP (5 mg/kg, body wt), the
rats lost body weight rapidly. The maximal decrease was shown
on day 4 (157 10 g vs. 197 14 g of controls, P < 0.05).
Subsequently, the body weights increased to their initial levels
by day 7 but still were less than those of the untreated control
rats (Table 1).
Serum creatinine levels rose to about double the control
levels on day 3 and on day 7. Although these levels were later
reduced, they remained considerably higher than those in the
controls. Creatinine clearance was decreased significantly on
day 3; on day 7, however, that value was still low but not
statistically significant (Table 2).
Morphologic changes in rat kidneys after CDDP treatment
Renal morphology in control and treated rats was observed
on day 3 and day 7 after CDDP administration. The renal tissues
were separated into two parts, the superficial cortex (Fig. 1 A,
B, and C) and the medulla (Fig. 1 D, E, and F).
On day 3 after CDDP treatment, pathologic changes were
prominent in the proximal tubules, consisting of large quantities
of S3, situated in the outer stripe of the outer medulla. Severe
morphologic alterations in S3 were in the form of focal tubular
necrosis formed by epithelial detaching and sloughing into the
tubular lumen and the denuding of the basal membrane. Mild
changes involved loss of the brush border and apical blebbing
(Fig. 1 B and E). In contrast, the glomerulus, Si and S2 of the
proximal tubule, TAL, DT, and CCT in the superficial cortex
and inner medulla showed little or no change.
On day 7 after the CDDP injection, the tubular epithelial
lining in the S3 appeared to be in the process of recovery. Most
S3 cells in the outer medulla were lined by the flattened
epithelia and had brush borders of variable heights (Fig. 1 C and
F), compared with those of the controls (Fig. 1 A and D).
Table 2. Effects of CDDP (5 mg/kg i.p.) on serum creatinine and
creatinine clearance in male rats
Serum creatinine
mg/dl
Creatinine clearance
mi/mm
Control 0.62 0.04 (N = 12) 0.72 0.12 (N 10)
Day 3 1.18 0.15 (N 7)" 0.33 0.08 (N 7)
Day 7 0.86 0.12 (N = 9) 0.36 0.11 (N = 7)
a P < 0.05 vs. controlb P < 0.005 vs. control
Glucose and ammonia production in rat kidney slices after
CDDP treatment
The chronologic pattern in renal metabolic changes was
determined using rat kidney slices. Cell injury has been shown
histologically to occur within one to two days after CDDP
treatment [6, 7, 91, but, in this early phase, there was no change
in either GLG (Table 3) or AMG (Table 4) from 2 mM glutamine.
On day 3 after CDDP treatment, when the morphologic damage
was most prominent, ammonia production was significantly
increased in the first (containing S 1 and S2) and third (contain-
ing S3 and TAL) slices. Later, on day 7, when the tubular
epithelia were morphologically regenerating, AMG was re-
duced in the deep third and fourth (containing CCT) slices. In
contrast, GLG did not change significantly in any slice during
the week.
Glucose production in rat tubule suspensions after CDDP
treatment
Table 5 summarizes the results of CDDP's effect on GLG
from 2 m substrates of glutamine, pyruvate and malate in
tubule suspensions. In control rats, among the three substrates,
the highest gluconeogenic activity in tubule suspensions was
obtained from pyruvate, the second highest from malate, and
the lowest from glutamine. This result was statistically signifi-
cant according to variance analysis. On day 4 after CDDP
treatment, GLG from every substrate tended to increase and
then, on day 7, to decrease from glutamine and malate, but
these changes were statistically insignificant.
Ammonia production in rat individual nephron segments
seven days after CDDP treatment
As shown in Figure 2, ammoniagenic activity from 2 mM
glutamine in control rats was detected in all nephron segments
tested; this activity was highest in SI, S2, and S3 of the
proximal tubule and lower in other segments such as TAL, DT,
and CCT. On day 7 following CDDP treatment, ammonia
production in S2 and S3 was reduced dramatically to 26% and
33% of the control values, respectively. At this time, there was
a slight reduction of AMG in Si and CCT, and an elevation in
TAL and DT. These values, however, were not statistically
significant.
Discussion
Numerous reports about the nephrotoxicity of CDDP have
been accumulating that reveal the effects of CDDP on clinical
profiles and renal morphology in human and animal studies.
Clinically, CDDP-induced acute renal failure has been associ-
ated with enzymuria involving N-acetyl-f3-D-glucosaminidase
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Fig. 1. Light micrographs of tubular lesions 3 days (B and E) and 7 days (C and F) after CDDP treatment, compared with control rat (A and D).
A to C and D to F show the superficial cortex and medulla, respectively. E represents the proximal tubules in the outer stripe of the outer medulla
3 days after CDDP treatment. In this lesion, most proximal tubules are S3 showing widespread tubular necrosis together with a great deaf of
necrotic debris in the tubular lumens. Inner medullary portions in E appear normal. F shows the proximal tubules in the outer stripe of the outer
medulla 7 days after CDDP treatment; they appear to be undergoing regeneration, showing flattening of the tubular epithelia. Focal tubular
necrosis, however, is still notable, with cellular debris in the tubular lumens. Inner medullary portions in F appear normal. (PAS; x85 for A, B,
C, D, E, and F).
[101 and glutamyl transpeptidase (y-GTP) [lii, urinary loss of levels of serum creatinine, blood urea nitrogen, and uric acid [1,
/32-microglobulin [4], amino aciduria [11], and serum electrolyte 2, 5, 6, 8, 9, 24, 25]. Morphologically, CDDP-induced nephro-
disturbances [31, which indicate broad proximal tubular dys- toxicity has been most thoroughly studied in rats and is char-
functions. This renal failure is also accompanied by increased acterized by selective tubular damage to S3 of the proximal
Nosaka et a!: Cisplatin nephrotoxicity 77
Table 3. Glucose production (nmol/30 mm/mg, dry weight) from 2
m substrates in rat kidney slices after CDDP treatment (5 mg/kg
i.p.)
Slice depth from surface, mm
1 2 3 4
From glutamine
Control (N = 14)
DayI(N=3)
Day2(N = 4)
Day3(N= 5)
Day7(N= 6)
7.5 2.1
8.6±4.9
8.2 2.2
9.9 3.6
3.8 2.0
6.7 1.9
8.8±2.1
10.5 4.9
3.6 0.9
2.4± 1.0
3.0 1.0
5.2±4.1
1.2 1.2
0.3 0.2
0.1±0.1
1.2 0.8
4.7±4.3
4.6 3.3
0.4 0.3
0.0±0.0
From pyruvate
Control (N = 6)
Day 7 (N = 6)
From malate
Control (N = 6)
Day 7 (N = 6)
26.3 5.5
17.1 5.2
50.8 10.2
36.6 6.3
16.6 5.5
14.0 1.8
33.3 3.9
33.1 4.5
12.6 3.6
9.9 2.6
18.1 4.4
10.2 2.9
1.2 0.8
2.3 0.6
5.6 2.4
3.0 1.1
Four 1 mm kidney slices were cut consecutively inward from the
surface of a rectangular block cut out along the corticomedullary axis.
After aerobic incubation at 37°C for 30 minutes with three 2 mM
substrates, the glucose produced was measured by the HK/G6PDH
method. Then each blotted sample was heated at 110°C for 60 minutes
to determine the dry weight. Gluconeogenic activity was estimated
from the dry weight of each slice.
Table 4. Ammonia production (nmoll30 mm/mg, dry weight) from 2
mM glutamine in rat kidney slices after CDDP treatment
(5 mg/kg i.p.)
Slice depth from surface mm
1 2 3 4
Control 74.5 12.1 96.2 12.9 147.2 21.0 166.0 20.5
(N= 11)
Day 1 74.9 13.4 118.2 24.3 101.3 36.6 168.6 19.2(N = 4)
Day 2 68.1 11.8 110.5 15.4 105.7 13.2 113.7 29.8(N = 4)
Day 3 135.6 25.9a 127.1 25.9 217.2 33.3° 182.2 9.1
(N =5)
Day 7 36.8 12.2 52.0 15.0 71.6 32.0° 64.9 17.0°(N = 5)
The procedure for preparation of kidney slices was similar to that
described in Table 3. After aerobic incubation with or without 2 mM
glutamine at 37°C for 15 minutes, the ammonia produced was measured
according to the method of Kun and Kearney [21]. Ammoniagenic
activity was calculated from the difference between samples with and
without glutamine, and estimated from the dry weight of each slice.
a P < 0.05 vs. control
tubules located in the outer stripe of the outer medulla, with less
tubular damage occurring in Si, S2, and distal tubules [6—9, 24].
Thus, until now, CDDP nephrotoxicity has been studied pri-
marily in terms of functional changes occurring on the whole
kidney and morphologic damage. To confirm these clinical and
morphologic disorders, it was necessary to examine the
changes in specific markers for each nephron segment following
CDDP treatment.
The dose of CDDP used here, 5 mg/kg body wt, was quite
large and had been shown previously to induce overt nephro-
toxicity [61. In the present study, the clinical effects of CDDP
were also checked by measuring changes in body weights
(Table 1) and serum creatinine levels (Table 2). These results
are similar to those reported previously [6—9, 241. Morphologic
Table 5. Glucose production (nmol/30 mm/mg protein) from 2 mM
substrates in rat kidney tubule suspensions after CDDP treatment
(5 mg/kg i.p.)
2 m Substrates
Pyruvate Glutamine Malate
Control (N = 14) 109.6 10.4 65.2 5.7 93.1 8.9
Day 4 (N = 7) 139.2 25.2 90.4 13.0 98.7 14.7
Day 7 (N = 5) 112.3 4.5 59.7 4.5 82.5 14.8
The tubule suspensions were prepared as follows. Kidneys were first
perfused and incubated with a solution containing collagenase and then
sliced. Next, kidney slices were dispersed by a voltex mixer and the
turbid medium was sieved through a set of nylon meshes graded from I
mm to 40 m in diameter. The sieved residue was centrifuged for 10
minutes at 300 x g, and the washed precipitate was used as the tubule
suspension. Gluconeogenic activity was measured by the same method
as described in Table 3, and finally estimated from the protein content
of each suspension.
changes in the kidney after the 5 mg/kg CDDP treatment in this
study also included widespread tubular necrosis and degenera-
tion, predominantly in S3 segment of the proximal tubules on
day 3 and regeneration of the affected tubular epithelia on day
7. These observations were in agreement with previous studies
[6—9, 24].
In our previous studies, we identified several functional
heterogeneities of normal rat nephron segments by the direct
measurement of glucose and ammonia production with ultrami-
cr0-assays [12, 13]. The highest gluconeogenic activity was
detected in Sl (45.4 5.7 and 58.0 6.0 pmollmm/hr from 2
mM pyruvate or glutamine, respectively). This activity was low
in S2 (9.9 2.2 and 4.8 1.1, respectively), and negligible in
S3, TAL, DT, and CCT [13]. In contrast to GLG, Nonoguchi,
Takehara and Endou [17] showed that ammonia production in
the normal rat nephron occurred broadly in all nephron seg-
ments tested, such as Sl, S2, S3, TAL, DT, and CCT, and was
highly and almost equally distributed in Si, S2, and S3 of the
proximal tubule. Additionally, chronic metabolic acidosis
caused a significant increase of both GLG [13] and AMG [17] in
SI and S2 [12], although there was no such response in S3.
Furthermore, TAL adapted by increasing AMG. Thus, within
the proximal tubule, GLG correlated with AMG in Sl and S2
under control and acidotic conditions, but no correlation was
present in S3. With these findings in mind, we performed this
study to examine the metabolic renal damage induced by
CDDP, using the method of directly measuring GLG and AMG
as functional markers of renal metabolism.
As described above, renal glucose production occurs mainly
in S 1, and it is reasonable to consider the capacity for glucose
production in kidney slices and tubule suspensions used here as
a function of Sl. On the other hand, since renal AMG is widely
distributed in each nephron segment, it is necessary to use
isolated nephron segments, in addition to kidney slices, to
evaluate functional changes among the various nephron seg-
ments.
The capacity for glucose production in kidney slices (Table 3)
and tubule suspensions (Table 5) was totally unaffected by
CDDP treatment. Thus, CDDP may not cause severe damage to
Si.
Our results concerning the CDDP effects on AMG indicated
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two distinctive dissociations between renal metabolic and mor-
phologic alterations induced by CDDP. First, AMG in the first
and third kidney slices was enhanced on day 3, when morpho-
logical damage was approaching maximum. This paradoxical
AMG increase on day 3 in the first slice might be due to
adaptation of Si to compensate for the dysfunction in S2 and
S3, because Si has been shown to have the largest capacity for
AMG in pathologic conditions such as chronic metabolic aci-
dosis [121. Similarly, increased AMG on day 3 in the third slice
might indicate hyperfunction of TAL. In contrast, GLG was
unaffected, because glucose production is by nature mainly
localized in the intact Si and compensatory hyperfunction of Sl
seems not to be necessary. Second, the significant reduction of
AMG on day 7 in S2 and S3 (Fig. 2) as well as in the third and
fourth slices (Table 4) might be distinguished from the morpho-
logical findings previously reported [6—9, 241 and from our
observations in this study, which indicated that while morpho-
logically the renal damages occurred predominantly in S3 and
inconspicuously in S2, regeneration of the epithelia was evident
at this stage. After acute tubular necrosis induced by mercuric
chloride, Toback et a! showed that demands for amino acids
were enhanced for the regeneration of tubular epithelia [26—28].
Thus, it is probable that AMG in S2 and S3 might decrease at
this stage, because amino acids essential for ammonia produc-
tion might be utilized instead for epithelial repair. In this study,
our method of directly measuring glucose and ammonia pro-
duced in isolated nephron segments is sensitive enough to
detect changes in cell functions. We were able to confirm more
clearly that the target sites of CDDP should be predominantly in
S2 and S3, not in Si.
The decrease in ammonia production activity in S2 and S3
appeared to be caused by the reduction of associated enzymes.
Fig. 2. Ammonia genesis along a single
nephron in rats, 7 days after CDDP
treatment. Compared with control rats (open
columns), ammoniagenic activity in S2 and
S3 of CDDP-treated rats (closed columns)
(4)(5) (41(6) was reduced dramatically (P < 0.005).Changes in Si, TAL, DT, and CCT were
DT CCT statistically insignificant.
Leyland-Jones et a! [11] showed that urinary loss of y-GTP
occurred after CDDP treatment, and that, concomitantly, the
content of y-GTP in the whole kidney decreased to about 74%
of the control 50 hours after the treatment. This enzyme is
thought to be identical to phosphate-independent glutaminase
[29, 301, which may act as one of the key enzymes and is highly
distributed in S2 and S3 segments U2]. The findings of Leyland-
Jones et al [11], therefore, may be supported and explained by
our present result.
In summary, our data in this study indicate that the major
target sites of CDDP in the rat kidney are located in S2 and S3
portions of the proximal tubule.
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